Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Size, Trends & Forecast | Major Players 2025 - Kamada Pharmaceuticals, Takeda Pharmaceutical Company Limited, CSL

"Type 1 Alpha-1 Antitrypsin Deficiency Treatment market expected to grow at a high CAGR during the forecast period (2024-2031)." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/type-1-alpha-1-antitrypsin-deficiency-treatment-market?sp

United States: Recent Industry Developments

✅ In September 2025, Grifols launched a next-generation intravenous AAT therapy with improved bioavailability and extended dosing intervals for patients with Type 1 Alpha-1 Antitrypsin Deficiency.

✅ In August 2025, CSL Behring completed the acquisition of AlphaThera, a U.S.-based biotech company specializing in gene therapy and protein augmentation treatments for AATD, expanding its rare disease portfolio.

✅ In July 2025, Vertex Pharmaceuticals invested $50 million to advance its AATD gene editing and protein replacement programs, supporting preclinical and early-phase clinical trials.

✅ In June 2025, Kamada Inc. launched an inhalable AAT therapy in the U.S., aimed at improving lung function and quality of life for patients with Type 1 Alpha-1 Antitrypsin Deficiency.

Japan: Recent Industry Developments

✅ In September 2025, Chugai Pharmaceutical initiated a Phase II trial of a novel AAT protein therapy targeting lung and liver manifestations of Type 1 Alpha-1 Antitrypsin Deficiency in Japanese patients.

✅ In August 2025, Takeda Pharmaceutical invested in expanding its rare disease R&D facility in Osaka to accelerate development of protein replacement and gene therapy solutions for AATD.

✅ In July 2025, Mitsubishi Tanabe Pharma completed the acquisition of a small biotech startup focusing on inhalable and subcutaneous AAT therapies, strengthening its pulmonary and rare disease pipeline.

✅ In June 2025, Kissei Pharmaceutical launched a new clinical study for long-acting AAT formulations in Japan, aimed at reducing infusion frequency while maintaining therapeutic efficacy.

Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market: Drivers

The Type 1 Alpha-1 Antitrypsin (A1AT) deficiency treatment market is witnessing growth due to increasing awareness and diagnosis of this genetic disorder, which affects the lungs and liver. Treatments aim to manage symptoms, slow disease progression, and improve patient quality of life through augmentation therapy, lifestyle management, and emerging gene therapies. Rising prevalence of respiratory complications, chronic obstructive pulmonary disease (COPD), and liver-related issues in A1AT patients is driving demand for effective therapies. Technological advancements in biologics, gene editing, and targeted therapeutic approaches are enhancing treatment efficacy and personalization. Additionally, expanding healthcare infrastructure and improved access to specialized care are supporting market adoption.

Innovation in recombinant A1AT products, inhalation therapies, and potential gene therapies is enabling more effective, patient-friendly, and long-term disease management options. Increasing screening programs and early diagnosis initiatives are encouraging timely intervention and therapeutic use. Regulatory support for orphan drugs and rare disease treatments is facilitating faster approval and market availability. Collaborations between biotechnology firms, research institutions, and healthcare providers are accelerating clinical development and knowledge dissemination. Collectively, these factors are driving steady growth in the Type 1 Alpha-1 Antitrypsin deficiency treatment market as stakeholders focus on improving patient outcomes and expanding access to advanced therapies.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/type-1-alpha-1-antitrypsin-deficiency-treatment-market?sp

Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market: Major Players

Kamada Pharmaceuticals, Takeda Pharmaceutical Company Limited, CSL, Vertex Pharmaceuticals Incorporated, Grifols, Arrowhead Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc, Inhibrx, Inc., Wave Life Sciences and Mereo Biopharma Group PLC among others.

Segment Covered in the Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market:

➥ By Treatment: Augmentation Therapy, Medication, Oxygen Therapy, Smoking Cessation Therapy, Others

➥ By Route of Administration: Inhaled, Intravenous, Others

➥ By End-user: Hospitals, Ambulatory Surgical Centers, Others

Research Process:

Both primary and secondary data sources have been used in the Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Research Industry:

➠ Who leads the Type 1 Alpha-1 Antitrypsin Deficiency Treatment industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Type 1 Alpha-1 Antitrypsin Deficiency Treatment market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Type 1 Alpha-1 Antitrypsin Deficiency Treatment market growth?
➠ What are the dominant sales and distribution strategies in the Type 1 Alpha-1 Antitrypsin Deficiency Treatment industry?

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=type-1-alpha-1-antitrypsin-deficiency-treatment-market

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.